uk 68798 has been researched along with encainide in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baizman, ER; Becker, C; Bell, RH; Birsner, NC; Bohnet, EA; Busacca, CA; Carabateas, PM; Chadwick, CC; Gruett, MD; Johnson, RE | 1 |
Topliss, JG; Yoshida, F | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
De Clerck, F; Lu, HR; Remeysen, P | 1 |
6 other study(ies) available for uk 68798 and encainide
Article | Year |
---|---|
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal; Dogs; Guinea Pigs; Heart Ventricles; Male; Myocardial Contraction; Myocardial Infarction; Potassium Channels; Rats; Rats, Sprague-Dawley; Refractory Period, Electrophysiological; Sodium Channels; Structure-Activity Relationship | 1993 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Antifibrillary action of class I-IV antiarrhythmic agents in the model of ventricular fibrillation threshold of anesthetized guinea pigs.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Atenolol; Benzopyrans; Chromans; Disease Models, Animal; Electric Stimulation; Electrocardiography; Encainide; Ethanolamines; Guinea Pigs; Heart; Heart Conduction System; Injections, Intravenous; Male; Metoprolol; Nebivolol; Phenethylamines; Piperidines; Sotalol; Sulfonamides; Ventricular Fibrillation; Verapamil | 1995 |